The X-ray repair cross-completing gene 1 (XRCC1) polymorphisms and lung cancer incidence – a confirmatory umbrella review of observational evidence
DOI:
https://doi.org/10.15584/ejcem.2025.1.29Keywords:
case-control, DNA repair, genetic susceptibility, lung cancer, meta-analysis, XRCC1 geneAbstract
Introduction and aim. Lung cancer (LC) is a leading cause of cancer-related deaths worldwide, with X-ray repair cross-comple menting gene 1 (XRCC1) playing a crucial role in DNA repair and influencing LC risk through genetic mutations. Despite nu merous meta-analyses, results have been inconsistent. This study systematically evaluated existing meta-analyses to clarify the association between XRCC1 gene variations and LC.
Material and methods. A comprehensive literature search was conducted using Scopus, Web of Science, Embase, and Co chrane databases. The present Umbrella review followed PRISMA and MOOSE guidelines. The AMSTAR tool assessed the meth odological quality of the included studies.
Analysis of the literature. A total of 28 data sets were analyzed: 9 for the rs25487 (codon 399), 11 for the rs1799782 (codon 194), and 8 for the rs25489 (codon 280) polymorphisms. Significant associations were found with odds ratios ranging from 0.93 to 1.92 (p<0.05) in 16 data sets. XRCC1 rs25487/codon 399 and rs1799782/codon 194 were strongly linked to LC risk, while rs25489 (codon 280) was not. Twelve datasets showed significant heterogeneity, and publication bias was not detected in 24 datasets. Most meta-analyses demonstrated high methodological quality.
Conclusion. These findings suggest that XRCC1 (rs25487/codon 399 and rs1799782/codon 194) gene polymorphisms have the potential to serve as biomarkers for the early identification and management of LC risk.
Downloads
References
Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemp Oncol (Pozn). 2021;25(1):45-52. doi: 10.5114/wo.2021.103829
Araujo LH, Horn L, Merritt RE, Shilo K, Xu-Welliver M, Carbone DP. Cancer of the lung: Non-small cell lung cancer and small cell lung cancer. Elsevier. Abeloff ’s Clinical Oncology. 2020:1108-1158. doi: 10.1016/B978-0-323-47674-4.00069-4
Myers DJ, Wallen JM. Lung adenocarcinoma. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK519578/. Accessed May 15, 2024.
Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3. doi: 10.1038/s41572-020-00235-0
Bidzinska J, Szurowska E. See lung cancer with an AI. Cancers. 2023;15(4):1321. doi: 10.3390/cancers15041321
Li W, Jia MX, Wang JH, et al. Association of MMP9-1562C/T and MMP13-77A/G polymorphisms with non-small cell lung cancer in southern Chinese population. Biomolecules. 2019;9(3):107. doi: 10.3390/biom9030107
Huang Y, Zhu M, Ji M, et al. Air pollution, genetic factors, and the risk of lung cancer: a prospective study in the UK Biobank. Am J Respir Crit Care Med. 2021;204(7):817-825. doi: 10.1164/rccm.202011-4063OC
Wang Y, Zhang M, Li Z, et al. Fine particulate matter induces mitochondrial dysfunction and oxidative stress in human SH-SY5Y cells. Chemosphere. 2019;218:577-588. doi: 10.1016/j.chemosphere.2018.11.149
James BA, Williams JL, Nemesure B. A systematic review of genetic ancestry as a risk factor for incidence of non-small cell lung cancer in the US. Front Genet. 2023;14:1141058. doi: 10.3389/fgene.2023.1141058
de Alencar VTL, Formiga MN, de Lima VCC. Inherited lung cancer: a review. Ecancermedicalscience. 2020;14:1008. doi: 10.3332/ecancer.2020.1008
Freitas C, Sousa C, Machado F, et al. The role of liquid biopsy in early diagnosis of lung cancer. Front Oncol. 2021;11:634316. doi: 10.3389/fonc.2021.634316
Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis. Int J Mol Sci. 2021;22(16):8661. doi: 10.3390/ijms22168661
Li W, Zhang M, Huang C, Meng J, Yin X, Sun G. Genetic variants of DNA repair pathway genes on lung cancer risk. Pathol Res Pract. 2019;215(10):152548. doi: 10.1016/j.prp.2019.152548
Liao Z, Yi M, Li J, Zhang Y. DNA repair in lung cancer: a large-scale quantitative analysis for polymorphisms in DNA repairing pathway genes and lung cancer susceptibility. Expert Rev Respir Med. 2022;16(9):997-1010. doi: 10.1080/17476348.2022.2115361
Singh A, Singh N, Behera D, Sharma S. Association and multiple interaction analysis among five XRCC1 polymorphic variants in modulating lung cancer risk in North Indian population. Dna Repair. 2016;47:30-41. doi: 10.1016/j.dnarep.2016.09.006
Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis. Environ Mol Mutagen. 2017;58(5):235-263. doi: 10.1002/em.22087
Demin AA, Hirota K, Tsuda M, et al. XRCC1 prevents toxic PARP1 trapping during DNA base excision repair. Molecular cell. 2021;81(14):3018-3030. doi: 10.1016/j.molcel.2021.05.009
Du Y, He Y, Mei Z, Qian L, Shi J, Jie Z. Association between genetic polymorphisms in XPD and XRCC1 genes and risks of non‐small cell lung cancer in East Chinese Han population. Clin Respir J. 2016;10(3):311-317. doi:10.1111/crj.12218
Wang L, Wang LL, Shang D, et al. Gene polymorphism of DNA repair gene X‐ray repair cross complementing group 1 and xeroderma pigmentosum group D and environment interaction in non‐small‐cell lung cancer for Chinese nonsmoking female patients. Kaohsiung J Med Sci. 2019;35(1):39-48. doi: 10.1002/kjm2.12007
Neuenschwander M, Ballon A, Weber KS, et al. Role of diet in type 2 diabetes incidence: umbrella review of meta-analyses of prospective observational studies. BMJ. 2019;366. doi:10.1136/bmj.l2368
Chen L, Zhuo D, Chen J, Yuan H. XRCC1 polymorphisms and lung cancer risk in Caucasian populations: a meta-analysis. Int J Clin Exp Med. 2015;8(9):14969.
Wang JY, Cai Y. X-ray repair cross-complementing group 1 codon 399 polymorphism and lung cancer risk: an updated meta-analysis. Tumor Biol. 2014; 35:411-418. doi:10.1007/s13277-013-1057-8
Zhang J, Zeng XT, Lei JR, Tang YJ, Yang J. No association between XRCC1 gene Arg194Trp polymorphism and risk of lung cancer: evidence based on an updated cumulative meta-analysis. Tumor Biol. 2014; 35:5629-5635. doi: 10.1007/s13277-014-1745-z
Li W, Li K, Zhao L, Zou H. DNA repair pathway genes and lung cancer susceptibility: a meta-analysis. Gene. 2014;538(2):361-365. doi: 10.1016/j.gene.2013.12.028
Huang G, Cai S, Wang W, Zhang Q, Liu A. Association between XRCC1 and XRCC3 polymorphisms with lung cancer risk: a meta-analysis from case-control studies. PloS one. 2013;8(8): e68457. doi: 10.1371/journal.pone.0068457
Guo QX, Yang WH, Zhai JF, Han FC, Wang CY. XRCC1 codon 280 polymorphism and susceptibility to lung cancer: a meta-analysis of the literatures. Tumor Biol. 2013;34(5):2989-2994. doi: 10.1007/s13277-013-0863-3
Dai L, Duan F, Wang P, Song C, Wang K, Zhang J. XRCC1 gene polymorphisms and lung cancer susceptibility: a meta-analysis of 44 case-control studies. Mol Biol Rep. 2012;39:9535-9547. doi: 10.1007/s11033-012-1818-2
Huang J, Zhang J, Zhao Y, et al. The Arg194Trp polymorphism in the XRCC1 gene and cancer risk in Chinese Mainland population: a meta-analysis. Mol Biol Rep. 2011;38:4565-4573. doi: 10.1007/s11033-010-0588-y
Jiang J, Liang X, Zhou X, et al. DNA repair gene X-ray repair cross complementing group 1 Arg194Trp polymorphism on the risk of lung cancer: a meta-analysis on 22 studies. J Thorac Oncol. 2010;5(11):1741-1747. doi: 10.1097/jto.0b013e3181f0c409
Kiyohara C, Takayama K, Nakanishi Y. Lung cancer risk and genetic polymorphisms in DNA repair pathways: a meta‐analysis. J Nucleic Acids. 2010;2010(1):701760. doi: 10.4061/2010/701760
Wang Y, Yang H, Li H, et al. Association between X-ray repair cross complementing group 1 codon 399 and 194 polymorphisms and lung cancer risk: a meta-analysis. Cancer Lett. 2009;285(2):134-140. doi: 10.1016/j.canlet.2009.05.005
Zheng H, Wang Z, Shi X, Wang Z. XRCC1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis. Lung Cancer. 2009;65(3):268-273. doi: 10.1016/j.lungcan.2009.02.002
Kiyohara C, Takayama K, Nakanishi Y. Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer. 2006;54(3):267-283. doi: 10.1016/j.lungcan.2006.08.009
Mossman BT, Gualtieri AF. Lung cancer: Mechanisms of carcinogenesis by asbestos. Occupational Cancers. 2020:239-256. doi:10.1007/978-3-030-30766-0_12
Liu HX, Li J, Ye BG. Correlation between gene polymorphisms of CYP1A1, GSTP1, ERCC2, XRCC1, and XRCC3 and susceptibility to lung cancer. Genet Mol Res. 2016;15(4):15048813. doi:10.4238/gmr15048813
Mok MC, Campalans A, Pillon MC, Guarne A, Radicella JP, Junop MS. Identification of an XRCC1 DNA binding activity essential for retention at sites of DNA damage. Sci Rep. 2019;9(1):3095. doi: 10.1038/s41598-019-39543-1
Zhu DQ, Zou Q, Hu CH, Su JL, Zhou GH, Liu P. XRCC1 genetic polymorphism acts a potential biomarker for lung cancer. Tumor Biol. 2015; 36:3745-3750. doi: 10.1007/s13277-014-3014-6
Karaagac M, Artac M, Geredeli C, et al. ERCC1 and XRCC1 single nucleotide polymorphisms can guide treatment decision in patients with metastatic non-small cell lung cancer. Medicine. 2020;9(1):255-260. doi: 10.5455/medscience.2019.08.9184
Minina VI, Bakanova ML, Soboleva OA, et al. Polymorphisms in DNA repair genes in lung cancer patients living in a coal-mining region. Eur J Cancer Prev. 2019;28(6):522-528. doi: 10.1097/cej.0000000000000504
Yang Z, Liu Z. Potential functional variants in DNA repair genes are associated with efficacy and toxicity of radiotherapy in patients with non‐small‐cell lung cancer. J Oncol. 2020;2020(1):3132786. doi: 10.1155/2020/3132786
Al-Rawi SS, Khalaf AA, Al-Jbouri AM, Jasim SA, Mutar AA. Association between XRCC-1 Arg194Trp polymorphism with lung cancer in Iraqi patients. Med J Babylon. 2023;20(3):638-641. doi: 10.4103/MJBL.MJBL_1014_23
Zhou S, Zhu Q, Liu H, et al. Associations of polycyclic aromatic hydrocarbons exposure and its interaction with XRCC1 genetic polymorphism with lung cancer: A case-control study. Environ Pollut. 2021;290:118077. doi: 10.1016/j.envpol.2021.118077
Ezzeldin N, El-Lebedy D, Mohammed A. Gene-environment and gene-gene interactions between CHRNA3rs1051730, X RCC1 rs25487, and ERCC1 rs735482 variants highly elevate the risk of lung cancer. Egypt J Med Hum Genet. 2019;20:1-7. doi:10.1186/s43042-019-0034-1
Karaagaç M, Geredeli C, Yıldırım MS, et al. The XRCC1 and TP53 gene polymorphisms are associated with advanced-stage disease and early distant metastasis at diagnosis in non-small cell lung cancer. J Cancer Res Ther. 2023;19(5):1248-1254. doi: 10.4103/jcrt.jcrt_1657_21
Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. JBI Evid Implement. 2015;13(3):132-140. doi: 10.1097/xeb.0000000000000055
Zhang N, Ouyang Y, Chang J, Liu P, Tian X, Yu J. Pharmacogenetic association between XRCC1 polymorphisms and response to platinum‐based chemotherapy in Asian patients with NSCLC: a meta‐analysis. Biomed Res Int. 2020;2020(1):3520764. doi: 10.1155/2020/3520764
Bushra MU, Rivu SF, Sifat AE, et al. Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh. Mol Biol Rep. 2020;47:7073-7082. doi: 10.1007/s11033-020-05771-2
Perez-Ramirez C, Canadas-Garre M, Alnatsha A, et al. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients. Pharmacogenomics J. 2019;19(2):164-177. doi: 10.1038/s41397-018-0014-8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
